(CNSX:MAXX),(CNSX:MAXX.CN),(Pinksheets:MAXXF),(PinkSheets:MAXXF),(Boerse Frankfurt – Freiverkehr:89N.F),(Boerse Frankfurt – Freiverkehr:89N), NEW Video: Lawson – Canada's First Big Step into Natural Hydrogenhttps://www.youtube.com/watch?v=lTTOwMxz_zo SASKATOON, Saskatchewan, Dec. 01, 2025 (GLOBE NEWSWIRE) — MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) (“MAX Power” or the “Company“) is pleased to announce that Ranjith (Ran) Narayanasamy has formally assumed the role of […]

(NASDAQ:PLUG), SLINGERLANDS, N.Y., Dec. 01, 2025 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the hydrogen economy, today begins its contract with NASA to supply up to 218,000 kilograms (480,000 pounds) of liquid hydrogen to NASA's Glenn Research Center in Cleveland, Ohio, and the Neil A. Armstrong

(NASDAQ:BGLC), KUALA LUMPUR, Malaysia and SINGAPORE, Dec. 01, 2025 (GLOBE NEWSWIRE) — BioNexus Gene Lab Corp. (“BGLC”) today announced that it has executed an Exclusive Intellectual Property License Agreement for Southeast Asia with Fidelion Diagnostics Pte. Ltd. (“Fidelion”) for the VitaGuard(TM) minimal residual disease (“MRD”) liquid biopsy platform. The license is a key condition precedent

(NasdaqGM:TECX), WATERTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) — Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in two upcoming investor conferences taking place in

(NasdaqGM:RZLV), Deal to Add approximately $70M Revenue and is immediately EBITDA-accretive, Expanding “Brain Commerce” Footprint Across US, UK & EMEA Advances roll-up strategy for upselling traditional search platforms and strengthens Rezolve's enterprise AI footprint across global markets A strategic 'return' for CEO Daniel Wagner, whose early product discovery technology underpins part of Crownpeak's platform, Unlocking

(NASDAQ:TKLF), Tokyo, Japan, Dec. 01, 2025 (GLOBE NEWSWIRE) — Tokyo Lifestyle Co., Ltd. (“Tokyo Lifestyle” or the “Company”) (Nasdaq: TKLF), a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic products, collectible cards, trendy toys as well as other products in Hong Kong, Japan, North America, Thailand, Vietnam and the

(NASDAQ:PODC), Premieres to Over 125 Million Pay Cable Subscribers and Free Streaming Viewers Via Envoy TV and Envoy FAST Channels, Dr. Phil Combined Social Following Tops 27 Million Network Debuts With More Than 200 Podcasts and 15,000 Hours of Premium Library Content Drawn From the Combined Catalogs of PodcastOne and Envoy Media Co. LOS ANGELES,

(HKSE:6855),(NasdaqGM:AAPG), ROCKVILLE, Md. and SUZHOU, China, Dec. 01, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company“), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that Chairman &

(NASDAQ:SLRX), Salarius subsidiary Decoy Therapeutics' influenza fusion inhibitors, designed using its proprietary IMP3ACT(TM) platform, show excellent in silico free energy binding to the viral target entry protein, supporting potential for anti-flu activity IMP3ACT's demonstrated capability to create a single antiviral therapeutic against influenza, COVID and RSV has potential to position Salarius to address large existing

(NasdaqGM:NEUP), BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) — Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statements to address what Neuphoria strongly believes is a campaign from Lynx1 Master Fund